U.S. Department of Justice Federal Bureau of Investigation

File No. 205-NK-2057320

U.S. Embassy Athens, Greece

22 June 2017

Chief Prosecutor Eleni Touloupaki Public Prosecutor's Office K. Loukareos 14 Athens, Greece 11522

RE: Novartis

Mrs. Touloupaki:

In our collaborative efforts in the parallel corruption investigation of Novartis pharmaceutical company, we are providing your office with the following information:

1. The below list identified those employees of Novartis Hellas who have been interviewed by Novartis attorneys as part of an internal investigation being conducted by Novartis.

Name	Positions			
Heinz Backes	CCFO, Finance			
	Head Finance Global Pharma IT			
	Finanz Experte, GIS FINANCE			
Eleni Bardi	Assistant			
	MKT & Sales Assistant			
	HR Administrator, HR Operations			
	HR Services Specialist - Tier 1, HR Operations			
Dimitris Bassias	Area Sales Manager			
	Pharmacy Account Manager/Head			
Martin Batzer	Head Pharma Affairs, Pharma Affairs Management			
	Head Novartis Basel Operations, Pharma Affairs Management			
	Head PH Basel Operations Management, PH Basel Operations			
	Management			
	Head NSC-CH Operations Mgmt, PH Novartis Service Center			
	Head Real Estate&Facility Services NBS, PH Novartis Service Center			
	Head REFS & NBS Country Rep, PH Novartis Service Center			
Elena Bodioti	Product Manager, Marketing General Medicines			
	Product Director, Marketing General Medicines			
	Key Account Marketing MGR			

UNCLASSIFIED

1	LV A counts Marketing Mar State Funds/Hospital KAM		
	Key Accounts Marketing Mgr, State Funds/Hospital KAM		
	Junior DRA Manager, DRA		
TY 11	DRA Manager, DRA Global Compliance Officer		
Damien Heller			
Eirini Karahaliou	Assistant		
	Pricing Assistant		
	Pricing & Reimbursement Associate		
Panagiota Karra	Conventions Manager		
	Conventions & Events Project Manager		
	Sr. Conv. & Events Project Mgr		
Marialena	Product Manager		
Konstantinidou	Medical Advisor		
	Head of Medical Oncology		
Efthymios Lioulias	Head Legal and Country President Support		
	Senior Legal Counsel, Region AMAC		
	Senior Legal Counsel		
Claude Menweg	Head of Accounts Receivable		
	Process Manager Financial Operations		
	Service Manager Invoices & Accounts Receivable		
Michail Michaleris	Marketing Sciences Mgr, General Medicines		
	ABGU Head and BD&L Head, General Medicines		
	HEAD IDTI & HEAD BD&L, General Medicines		
	BF Head IDTI, General Medicines		
	BF Head Specialty Business, General Medicines		
	Head Neuroscience BF		
75 1 2771 1 1 1	Head Neuroscience Franchise		
Despina Nikolaidis	ICRO MANAGER EMEA SOUTH, Medical		
	Brand Director, marketing		
	Brand Director, IHC AI Marketing		
	National Sales Manager, Speciality		
A41 ' 0.1 C	Head Immunology & Dermatology Franchise		
Athanasios Sakorafas	Junior Payors Relations		
	Public Affairs & Payor Relations Manager		
Marila Califa	Oncology Market Access and Public Affairs		
Marilena Salichou	Tactical Buyer		
	Country Buyer		
Augusta	Senior Buyer		
Anastasia Sarakatsianou	C&E IND.BOOK. COORD		
Sarakatsianou	Conv. & Events Ind. Book. Coord., Conventions & Events		
Toon your O 1	MSO Coordinator, MSO		
Jaap van Oerle	Regional Audit Manager, Internal Audit - Europe I		
	Regional Hd Internal Audit & Deputy Hd IA, Auditing		
	Regional Hd Internal Audit&Head IA a.i., Auditing		
	Regional Head Internal Audit, Internal Audit - Europe I		

Monika Daniela Wernli	Accountant – Third Party Debtors AR/IC Specialist, Order to Cash
	FRA Specialist IC/TCM
Chrysanthi Zoi	Market Research Manager
	BD&L Manager
	Senior Pricing & Reimbursement Manager

2. Swiss Bank Account Information which may be related to payments made in Greece:

Bank	Beneficiary	IBAN / Account	Status
	NOVARTIS PHARMA		Closed
UBS	AG	CH9000230230EW1014181	

3. Additional bank account information provided by the Novartis attorneys in regard to accounts utilized by Novartis Hellas:

Bank	Beneficiary	IBAN / Account	Status
	NOVARTIS HELLAS		Active
ALPHA BANK	AEBE	GR4301401010101002320003834	
	NOVARTIS HELLAS		Active
ALPHA BANK	AEBE	GR0501401010101002320010920	
	NOVARTIS HELLAS		Closed
ALPHA BANK	AEBE	GR8501401010101002030099954	
NATIONAL BANK OF	NOVARTIS HELLAS		Active
GREECE	AEBE	GR1301107200000072047014377	
	NOVARTIS HELLAS		Active
PEIRAEUS	AEBE	GR6201710170006017040044223	~ 1
	NOVARTIS HELLAS	CD 5 40 4 50 000 50 00 50 00 50 00 50 00 50 00 50 00 50 00 50 00 50 00 50 00 5	Closed
PEIRAEUS	AEBE	GR5401720350005035022727008	
	NOVARTIS HELLAS	GD00004000400000444554065	Active
CITI	AEBE	GR8008400010000000444774365	
	NOVARTIS HELLAS	CD 400040001000000444554010	Active
CITI	AEBE	GR4008400010000000444774018	
	NOVARTIS HELLAS	CD #20040001000000444#74006	Active
CITI	AEBE	GR7308400010000000444774006	G1 1
DAME DA DADA G	NOVARTIS HELLAS	0000000114200116	Closed
BNP PARIBAS	AEBE	0000000114390116	C1 1
BNP PARIBAS	NOVARTIS HELLAS	0000000114392056	Closed

	AEBE		4
	NOVARTIS HELLAS	•	Active
DEUTSCHE BANK AG	AEBE	DE47760700120043001700	
	NOVARTIS HELLAS		Closed
ATE BANK	AEBE	0170400442236	

4. <u>List of Novartis US employees who may have connections to Novartis Hellas. The FBI and United States Attorney's Office in Newark, New Jersey anticipate contacting these individuals with the intent to interview them. If any interviews are conducted, the results of those interviews will be provided to your office.</u>

Stavros Ntogiakos, a current Novartis employee, was based at Novartis Hellas as a product manager from approximately September 2008 through August 2011. In approximately August 2011, Mr. Ntogiakos transferred to Novartis Pharma Canada, where he worked as a brand manager until approximately July 2012, when he took on a role as a global brand manager for Novartis in Switzerland. Mr. Ntogiakos left Switzerland in approximately August 2016 for a Marketing Director position at Novartis Pharmaceuticals Corporation (NPC), East Hanover. His current title at NPC is Executive Director, Marketing – Eye Care.

Vijay Iyengar, a former Novartis employee, worked at NPC from approximately February 2003 to July 2009 in various roles in Global Oncology, including as product director and senior product director. From approximately July 2009 to November 2011, he served as VP of the Oncology Business Unit at Novartis Hellas. In approximately November 2011, Mr. Iyengar transferred back to NPC as VP of the Oncology Rare Diseases Franchise. From approximately April 2014 until his departure in April 2016, Mr. Iyengar served as President of Genoptix, a Novartis company.

Christian Klee, a current Novartis employee, was based at Novartis Pharma AG in Basel from approximately July 2001 to July 2005 as the Head of Finance for Pharma. From approximately July 2005 to October 2008, he served as the Global Head of Finance for Pharma. In approximately October 2008, Mr. Klee transferred to the Novartis Institutes for BioMedical Research (NIBR), where he served as the CFO from approximately October 2008 to July 2016. In approximately July 2016, Mr. Klee started in his current role as the COO of NIBR and the CCFO USA.

If any of the above names or bank account information is recognized by your office, we would appreciate the chance to discuss their relevance to the Novartis investigation.

As always, we appreciate the cooperation our agencies share on such a critical issue, and stand ready to assist you whenever necessary. If you have any questions regarding this (information, please do not hesitate to contact me at 210-720-2455.

Sincerely,

Aristides Papadacos

Legal Attaché

U.S. Embassy Athens